Vein

The National Institute for Health and Care Excellence (NICE) has recommended Daiichi Sankyo’s Lixiana (edoxaban tosylate) to treat patients suffering from blood clots in the legs and lungs.

NICE has recommended the drug to treat and prevent recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Edoxaban tosylate is an oral anticoagulant, which directly inhibits factor X (factor Xa) that is a crucial component in the formation of blood clots.

It is one of the class of blood-thinning drugs called non-VKA oral anti-coagulants (NOACs), which are used as an alternative to warfarin.

Edoxaban has already obtained European marketing approval to treat DVT and PE, as well as to prevent recurrent DVT and PE in adults.

See Also:
"We are very pleased to be able to offer patients and doctors in England and Wales a new easy-to-use alternative in the treatment armoury against VTE."

Daiichi Sankyo UK general manager Dr Simon Clough said: "We are very pleased to be able to offer patients and doctors in England and Wales a new easy-to-use alternative in the treatment armoury against VTE."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The global Phase III trial Hokusai-VTE study assessed the efficacy and safety of edoxaban against warfarin in 8,292 patients with either acute symptomatic deep vein thrombosis, pulmonary embolism, or both.

According to the firm, the trial demonstrated that edoxaban met the primary efficacy endpoint of non-inferiority compared to warfarin, following initial use of heparin in both arms, for the treatment and prevention of recurrent symptomatic VTE.

NICE health technology evaluation centre director professor Carole Longson said: "The newer oral anticoagulants like edoxaban tosylate are an alternative to warfarin as the mainstay of treatment to prevent recurrent blood clots, however their use shows wide variation across the country."

Image: DVT in the right leg with swelling and redness. Photo: courtesy of James Heilman, MD.